Sanofi
About Sanofi
Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients' daily life, wherever they live and enable them to enjoy a healthier life.
Recent News
EMA’s CHMP Backs Six New Products in January
Innate Pharma to Participate in the Kempen Life Sciences Conference
New Yellow Fever Vaccine Matches Safety and Effectiveness of Current Shot
The Evolving BTK Story in Multiple Sclerosis: Clinical Report
Diagonal Banks Another $125M for ‘Clustering’ Antibody Drugs
Pipeline Cuts for Sanofi; Breakthru Medicine Raises $60M
Burnout Common but Regrets Are Not in Allergy, Immunology
Sanofi’s Venglustat Succeeds in Phase 3 Gaucher Trial but Fails Separate Study in Fabry Disease
Sanofi Extends $180M to California T Cell Engager Startup Kali
World Hemophilia Day 2026: New Treatment Era and Improving Diagnosis
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
Ocugen Shares Fall, Despite Positive Eye Disorder Trial
Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
Amgen Adds AML Candidate in Deal for U.K.-based Dark Blue: Deals Report
‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s 'Anti-Science' Vaccine Policies
EU Approves Dupixent for Children 2‑11 with Chronic Spontaneous Urticaria
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
WEF Highlights 32 AI Case Studies with Real-World Business Impact
Proteasomes: A Novel Approach to Target the Immune System
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
Top Biotech Deals in March 2026
TrumpRx Delayed Amid Potential Anti-Kickback Concerns
AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch
FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
BrightInsight Secures $13M Funding Round
Facing Talent Crunch, Radiopharma Field Casts a Wide Net
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China
QuantHealth Achieves 8x Financial Growth Across Life Sciences Engagements
Call Goes Out for Type 1 Diabetes Screening in UK
Mixed Data Mars Sanofi's Venglustat Programme
5 Questions Facing Biopharma in 2026
ABB Showcases the Future of Lab Automation at SLAS 2026
Zip Launches Enterprise Transformation Office, Tapping Former Fortune 500 CPOs to Guide Procurement Leaders Through AI-Era Change
Enable Injections Scoops Up $30M
FDA Grants Full Approval to Travere’s FILSPARI for FSGS, Unlocking $2B Market
Lifordi Immunotherapeutics Inks New Funding
Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial
Bipartisan INSULIN Act Seeks $35 Monthly Cap for Privately Insured Patients
The New Gold Rush in Brain Science
Ongoing Regulatory Uncertainty Means Innovation Is Now Higher Risk
Sanofi Moves Away From mRNA Flu Vaccine as CEO Projects Confidence
Boehringer Signs €1bn+ Deal for Simcere IBD Candidate
Sanofi Expects Vaccine Sales Growth to Dip Amid ‘Challenging Environment’
2025 Novel Large Molecule FDA Drug Approvals
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Sanofi's Bispecific Lunsekimig Has Mixed Readouts in Phase 2
Recent Deals
Enable Injections Secures $30M Corporate Investment From Sanofi
Alveus Therapeutics Secures $37M Series A Extension Funding
Electra Therapeutics Raises $183M Series C to Fund Pivotal Rare Disease Trial
Sanofi Invests $180M in T-Cell Engager Startup Kali
Electra Therapeutics Raises $183M in Series C Led by Nextech and EQT Life Sciences
